Condition: Plaque Psoriasis · Sponsor: Oruka Therapeutics, Inc.
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
This description comes directly from the study's public registry record.
Oruka Clinical Trials Information · 781-560-0299 · clinicaltrials@orukatx.com
Always discuss trial participation with your own doctor first.
| Oruka Therapeutics Investigative Site | Phoenix, Arizona, United States | Recruiting |
| Oruka Therapeutics Investigative Site | North Little Rock, Arkansas, United States | Recruiting |
| Oruka Therapeutics Investigative Site | Los Angeles, California, United States | Recruiting |
| Oruka Therapeutics Investigative Site | Los Angeles, California, United States | Recruiting |
| Oruka Therapeutics Investigative Site | San Diego, California, United States | Recruiting |
| Oruka Therapeutics Investigative Site | Miami, Florida, United States | Recruiting |
| Oruka Therapeutics Investigative Site | Rolling Meadows, Illinois, United States | Recruiting |
| Oruka Therapeutics Investigative Site | Plainfield, Indiana, United States | Recruiting |
| Oruka Therapeutics Investigative Site | Rockville, Maryland, United States | Recruiting |
| Oruka Therapeutics Investigative Site | Kew Gardens, New York, United States | Recruiting |
| Oruka Therapeutics Investigative Site | Chapel Hill, North Carolina, United States | Recruiting |
| Oruka Therapeutics Investigative Site | Cleveland, Ohio, United States | Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07290569